|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
US7550590B2
(en)
|
2003-03-25 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
|
EP1659155B1
(en)
|
2003-08-25 |
2016-11-16 |
Kaneka Corporation |
Curing composition with improved heat resistance
|
|
US7790734B2
(en)
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
CN102127057A
(zh)
|
2004-03-15 |
2011-07-20 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
|
WO2006020564A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Smithkline Beecham Corporation |
Pyrimidin derivatives for the treatment of multiple myeloma
|
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
GEP20135838B
(en)
|
2005-09-14 |
2013-06-10 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors usage at diabetes treatment
|
|
CN101360723A
(zh)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
|
PL1954281T3
(pl)
|
2005-11-29 |
2011-07-29 |
Novartis Ag |
Sposób leczenia raka
|
|
HRP20100559T1
(hr)
*
|
2005-11-29 |
2010-11-30 |
Glaxosmithkline Llc |
Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
NZ580671A
(en)
|
2007-04-16 |
2012-03-30 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine derivatives
|
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
|
SG2014015085A
(en)
|
2008-04-16 |
2014-06-27 |
Portola Pharm Inc |
2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
NZ588830A
(en)
|
2008-04-22 |
2012-11-30 |
Portola Pharm Inc |
Inhibitors of protein kinases
|
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
|
EP2490536A4
(en)
*
|
2009-10-23 |
2013-04-17 |
Glaxo Wellcome Mfg Pte Ltd |
COMPOSITION AND METHOD
|
|
WO2011058179A1
(en)
|
2009-11-16 |
2011-05-19 |
Ratiopharm Gmbh |
5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
|
|
WO2011069053A1
(en)
|
2009-12-04 |
2011-06-09 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
|
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
|
EP2635556B1
(en)
|
2010-11-01 |
2017-06-21 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as syk modulators
|
|
US9150547B2
(en)
|
2010-11-29 |
2015-10-06 |
Hetero Research Foundation |
Process for the preparation of pazopanib using novel intermediate
|
|
CN102060848B
(zh)
*
|
2010-12-09 |
2013-09-18 |
天津药物研究院 |
芳香胺取代的嘧啶衍生物的制备及用途
|
|
CA3094793A1
(en)
|
2011-11-23 |
2013-05-30 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
CN103319410B
(zh)
*
|
2012-03-22 |
2016-04-06 |
天津药物研究院 |
一种吲唑化合物的合成方法
|
|
CN103373963B
(zh)
*
|
2012-04-28 |
2015-07-08 |
上海医药工业研究院 |
盐酸帕唑帕尼的中间体及其制备方法
|
|
CN103373989B
(zh)
*
|
2012-04-28 |
2016-04-13 |
上海医药工业研究院 |
盐酸帕唑帕尼的中间体的制备方法
|
|
US9676756B2
(en)
|
2012-10-08 |
2017-06-13 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
WO2014097152A1
(en)
*
|
2012-12-17 |
2014-06-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of pazopanib or salts thereof
|
|
EP2935250B1
(en)
|
2012-12-17 |
2018-03-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of pazopanib or salts thereof
|
|
CN103232443B
(zh)
*
|
2013-02-01 |
2014-12-10 |
天津药物研究院 |
一种吲唑衍生物的晶型及其制备和用途
|
|
CN103450085B
(zh)
*
|
2013-08-15 |
2015-11-18 |
凯莱英医药集团（天津）股份有限公司 |
一种盐酸帕唑帕尼关键中间体的制备方法
|
|
US10730859B2
(en)
|
2013-11-05 |
2020-08-04 |
Laurus Labs Limited |
Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
|
|
CN106565688B
(zh)
*
|
2016-11-11 |
2018-08-31 |
重庆医科大学 |
帕唑帕尼二聚体及其制备方法和用途
|
|
CN110028495B
(zh)
*
|
2019-05-24 |
2019-12-03 |
济南爱思医药科技有限公司 |
帕唑帕尼盐酸盐的制备方法
|
|
CN116554106A
(zh)
*
|
2023-04-28 |
2023-08-08 |
扬州市普林斯医药科技有限公司 |
一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法
|